Efficacy, safety, and immunogenicity of an Escherichia coli-produced nine-valent human papillomavirus vaccine: a multicentre, double-blind, randomised, controlled, phase 3 trial. (linkinghub.elsevier.com)

Authors: Pan HX … Xia NS Journal: Lancet Infectious Diseases Published: 2026-06-30 DOI: https://doi.org/10.1016/S1473-3099(26)00221-5